1. Abstract 528: Selectin-Binding Peptide Conjugate Molecule Decreases Murine Deep Vein Thrombosis Formation
- Author
-
Andrea M Chambers, James R Wodicka, Gurneet S Sangha, Alyssa Panitch, and Craig Goergen
- Subjects
cardiovascular system ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine - Abstract
Introduction: Deep vein thrombosis (DVT) affects 300,000 to 600,000 people annually with a recurrence in 20-50% after 10 years. Treatment is managed through anticoagulant drugs, but side effects occur due to systemic administration. The venous endothelium is thought to perpetrate thrombosis, especially through endothelial cell surface adhesion receptors P-selectin and E-selectin. In this study, a selectin receptor-binding molecule (EC-SEAL), made with a selectin-binding peptide and dermatan sulfate backbone was used to evaluate thrombus prevention in the infrarenal vena cava (IVC) of a mouse over 24 hours using high frequency ultrasound. Purpose: P-selectin and E-selectin have exemplified a link between DVT, leukocyte accumulation and rolling, and platelet binding. Thus, the purpose was to evaluate the ability of EC-SEAL to reduce leukocyte and platelet binding, and subsequently DVT, in a mouse model by blocking the corresponding endothelial cell receptors. Methods: A surgical murine model of thrombosis was induced by IVC stenosis with non-absorbable 6-0 silk suture and a 30-gauge needle (male C57BL/6; 10.8 ± 0.2 weeks old). The stenosis led to a 90% reduction in blood flow through the vessel. Within 10 minutes of suture placement around the IVC, 100 μl of saline (n = 6), EC-SEAL (n = 4), or heparin (n = 6) were systemically injected via the tail vein. Thrombus was observed before surgery, 6 hours and 24 hours after surgery using the Vevo 2100 high frequency ultrasound (FUJIFILM VisualSonics Inc.). Thrombus volume and IVC volume were analyzed using 3D ultrasound images, while thrombus weight was measured ex vivo . Results and Conclusions: Six hours after post-ligation, the mean thrombus percentage (thrombus volume/total IVC volume) was 63.1±5.3% for saline, 25.8±11.2% for EC-SEAL, and 26.1±11.4% for heparin. EC-SEAL and heparin groups had significantly lower 6-hour mean thrombus percentage (p < 0.05; ANOVA with a Tukey HSD post-hoc). The 24-hour mean thrombus percentage and thrombus weight were not statistically significant. The data suggest EC-SEAL reduces thrombus at 6 hours while avoiding reduced clotting time side effects associated with heparin. Further work will be needed to determine the true potential for EC-SEAL as a DVT treatment.
- Published
- 2017
- Full Text
- View/download PDF